Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.

Hector Jose Esquer

TitlePost-Doctoral Fellow
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Rinaldetti S, Zhou Q, Abbott JM, de Jong FC, Esquer H, Costello JC, Theodorescu D, LaBarbera DV. High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes. Int J Mol Sci. 2022 Sep 14; 23(18). PMID: 36142576.
      View in: PubMed
    2. Prutton KM, Marentette JO, Leifheit BA, Esquer H, LaBarbera DV, Anderson CC, Maclean KN, Roede JR. Oxidative stress as a candidate mechanism for accelerated neuroectodermal differentiation due to trisomy 21. Free Radic Biol Med. 2022 06; 186:32-42. PMID: 35537597.
      View in: PubMed
    3. Prigaro BJ, Esquer H, Zhou Q, Pike LA, Awolade P, Lai XH, Abraham AD, Abbott JM, Matter B, Kompella UB, Messersmith WA, Gustafson DL, LaBarbera DV. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022 03 10; 65(5):3943-3961. PMID: 35192363.
      View in: PubMed
    4. Esquer H, Zhou Q, Nemkov T, Abraham AD, Rinaldetti S, Chen YC, Zhang X, Orman MV, D'Alessandro A, Ferrer M, Messersmith WA, LaBarbera DV. Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer. Oncogene. 2021 04; 40(16):2884-2897. PMID: 33742123.
      View in: PubMed
    5. Abbott JM, Zhou Q, Esquer H, Pike L, Broneske TP, Rinaldetti S, Abraham AD, Ramirez DA, Lunghofer PJ, Pitts TM, Regan DP, Tan AC, Gustafson DL, Messersmith WA, LaBarbera DV. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Mol Cancer Ther. 2020 08; 19(8):1598-1612. PMID: 32499299.
      View in: PubMed
    6. Esquer H, Zhou Q, Abraham AD, LaBarbera DV. Advanced High-Content-Screening Applications of Clonogenicity in Cancer. SLAS Discov. 2020 08; 25(7):734-743. PMID: 32484006.
      View in: PubMed
    7. Abraham AD, Esquer H, Zhou Q, Tomlinson N, Hamill BD, Abbott JM, Li L, Pike LA, Rinaldetti S, Ramirez DA, Lunghofer PJ, Gomez JD, Schaack J, Nemkov T, D'Alessandro A, Hansen KC, Gustafson DL, Messersmith WA, LaBarbera DV. Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer. J Med Chem. 2019 11 27; 62(22):10182-10203. PMID: 31675229.
      View in: PubMed
    8. Lazarus LS, Esquer HJ, Anderson SN, Berreau LM, Benninghoff AD. Mitochondrial-Localized Versus Cytosolic Intracellular CO-Releasing Organic PhotoCORMs: Evaluation of CO Effects Using Bioenergetics. ACS Chem Biol. 2018 08 17; 13(8):2220-2228. PMID: 29932318.
      View in: PubMed
    9. Lazarus LS, Esquer HJ, Benninghoff AD, Berreau LM. Sense and Release: A Thiol-Responsive Flavonol-Based Photonically Driven Carbon Monoxide-Releasing Molecule That Operates via a Multiple-Input AND Logic Gate. J Am Chem Soc. 2017 07 19; 139(28):9435-9438. PMID: 28677975.
      View in: PubMed
    10. Anderson SN, Richards JM, Esquer HJ, Benninghoff AD, Arif AM, Berreau LM. A Structurally-Tunable 3-Hydroxyflavone Motif for Visible Light-Induced Carbon Monoxide-Releasing Molecules (CORMs). ChemistryOpen. 2015 Oct; 4(5):590-4. PMID: 26491637.
      View in: PubMed
    Esquer's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description

    Copyright © 2023 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)